UAE – Molecular diagnostics manufacturing companies AstraGene and Mylab Discovery Solutions have formed a new joint venture (JV) to design, develop, and commercialize fully-automated molecular diagnostics in the Middle East.
This agreement builds on AstraGene’s vision to emerge as a leading manufacturer and marketer of in-vitro diagnostic reagents, kits, and instruments both nationally and internationally.
AstraGene is Middle East’s first molecular diagnostics manufacturing company located in Dubai at Dubai Science Park, UAE.
AstraGene and Indian diagnostic company Mylab will jointly market automated molecular diagnostics in Kuwait and across the United Arab Emirates (UAE) in the coming months.
The joint statement said: “Mylab and AstraGene will co-develop molecular diagnostic solutions, including reagents, kits, and fully-automated devices.”
This partnership will pave the way for the upgrading of laboratory infrastructure in the UAE and Kuwait, and supports the installation of advanced diagnostic systems in the laboratories.
Furthermore, Pune-based Mylab has expanded its presence in the UAE and Kuwait through a joint venture designed to empower laboratories across the Middle East.
In his address, Hasmukh Rawal, Managing Director of Mylab, underscored: “This partnership is a step towards expanding our presence in the fast-growing molecular diagnostics markets.”
This partnership marks Mylab’s latest international market expansion and supports the company’s strategy to make high-quality diagnostics more accessible worldwide
Moreover, the combination of Mylab’s comprehensive product portfolio of molecular diagnostic kits and AstraGene’s local expertise in the space will enable laboratories in the region to drive better health outcomes.
The news comes a little over a week after Mylab joined forces with DnaNudge, a British company specializing in DNA testing, to develop and bring to market next-generation molecular diagnostic solutions for diabetic foot ulcer detection.
In February 2023, the Indian diagnostic company launched its novel rapid antigen tests for the diagnosis of sexually transmitted diseases, namely Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and Syphilis.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
